Last reviewed · How we verify
LYL314
At a glance
| Generic name | LYL314 |
|---|---|
| Sponsor | Lyell Immunopharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of LYL314 in Aggressive Large B-Cell Lymphoma (PHASE1, PHASE2)
- A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LYL314 CI brief — competitive landscape report
- LYL314 updates RSS · CI watch RSS
- Lyell Immunopharma, Inc. portfolio CI